// App-Quantinova.ai

5179 : Isatuximab based combinations induce potent tumor growth inhibition in pre-clinical models of multiple myeloma and acute lymphocytic leukemia

Researchers

Presenter

  • Chen Zhu

Principal Investigators

  • Celine Nicolazzi

  • Helgi Van de Velde

  • Dmitri Wiederschain

  • Sukhvinder Sidhu

  • Marielle Chiron

Medical Centers

  • Sanofi, Cambridge, MA

  • Sanofi R&D, Vitry-Sur-Seine, France

Locations

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Solid malignancies

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • carfilzomib Intravenous

  • Vincristine

  • Bortezomib

  • Cytarabine liposomal

  • Isatuximab

  • Adenosine

  • Adenosine Intravenous

  • Melphalan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved